ASX-listed Echo IQ has obtained regulatory approval in the United States for its AI-driven solution that supports structural heart disease diagnosis.
WHAT IT'S ABOUT
Two years since coming to the US, the company has now received 510(k) clearance from the Food and Drug Administration for EchoSolv AS, which is specifically indicated to support the diagnosis of severe aortic stenosis (a form of...
ASX-listed medical AI company Echo IQ has launched its cloud-based platform for screening structural heart disease in the United States.
WHAT IT DOES
The software platform called EchoSolv supports the identification of structural heart diseases, including guideline-defined aortic stenosis at present, automating this process using AI. It can also complete bulk assessments at a rate of up to 48,000...
